Sci.bio Recruiting

The biotech industry is entering a clear inflection point, driven by two major shifts happening simultaneously: how drugs are discovered and how they are reviewed. On one side, AI-driven drug discovery continues to attract significant investment, moving the industry further away from traditional “AI-assisted” workflows and toward fully integrated, AI-native development models. The focus is no longer just on accelerating research; it’s on reshaping how pipelines are designed from the start. On the regulatory side, the FDA is advancing initiatives aimed at modernizing clinical trials through more continuous, real-time data exchange between sponsors and regulators. If adopted at scale, this could meaningfully compress traditional development timelines and change how clinical decision-making is operationalized. Together, these shifts signal a broader evolution across biotech: Faster, more adaptive development models Deeper integration between data, technology, and regulatory strategy Increased demand for cross-functional talent who can operate in more dynamic development environments For organizations, this isn’t just a technology shift, it’s an operating model shift. As these changes move from pilots and capital investment into standard practice, the question becomes less if the industry changes and more about how quickly teams can adapt. At Sci.bio, we’re seeing increasing demand for talent that can bridge this gap, professionals who understand both the science and the systems behind how modern drug development is evolving. Read More: https://loom.ly/FzArNkM #Biotech #Biotechnology #BiotechJobs #AIinHealthcare #AIDrugDiscovery

Great partnerships are built on trust, transparency, and consistency. We pride ourselves on being accessible, bringing deep industry expertise, and delivering highly qualified talent, without the noise. A thoughtful, quality-first approach paired with clear communication is what drives efficient and effective hiring outcomes. If you’re looking for a recruiting partner who values precision, fairness, and long-term relationships, let’s chat: info@sci.bio #ClientFeedback #LifeSciences #Biotech #Recruiting #Partnership

In this Q&A with Lauren Money, we discuss how the market has shifted over the past year, where companies are struggling most in the hiring process, and what it takes to secure top biotech talent today consistently. While candidate volume remains high, the key challenge is efficiently identifying the right fit and moving quickly enough to stay competitive. At Sci.bio Recruiting, we help streamline this process by delivering curated, high-quality candidate pipelines built on deep scientific understanding and market expertise. From Biostatistics to Regulatory Affairs and beyond, we focus on precision hiring that speeds up work, improves clarity, and delivers better outcomes. In today’s market, better hiring comes down to doing the right things faster. Learn More: info@sci.bio #BiotechHiring #LifeSciences #Recruiting #TalentAcquisition

Biotech continues to move fast, and this week was a reminder of how quickly the landscape can shift. From major FDA leadership changes to a rebound in biotech IPO activity, the industry saw a mix of uncertainty, momentum, and continued innovation across cell therapy and oncology. What trend do you think will have the biggest impact on biotech for the rest of 2026? Read More: https://lnkd.in/eV4tRjd3 https://lnkd.in/eRy_u8hP https://lnkd.in/eZXSrgh2 https://lnkd.in/ex6dupWx https://lnkd.in/ex6dupWx https://lnkd.in/egRTv7U5 #Biotech #Biopharma #LifeSciences #FDA #BiotechNews #Pharma #BiotechIndustry

At Sci.bio Recruiting, staying connected to the life sciences industry means showing up where the science, innovation, and talent conversations are happening. Our team is actively engaged across biotech and life sciences conferences, industry events, and networking forums—building relationships, staying close to market trends, and deepening our understanding of where the industry is headed. These touchpoints matter. They help us: 1. Stay current on emerging science and hiring needs 2. Strengthen relationships with clients and candidates 3. Bring real-time market insight back to the teams we support 4. Better align talent with the evolving needs of the industry For us, recruiting doesn’t happen in isolation; it happens in the middle of the industry itself. #Biotech #LifeSciences #Networking #IndustryEvents #TalentAcquisition

Will AI fundamentally change the future of drug discovery? Alphabet-backed Isomorphic Labs recently raised a massive $2.1B Series B to advance its AI-driven drug discovery platform, another major sign of how much momentum is building at the intersection of biotech and artificial intelligence. As investment continues pouring into AI-first biotech companies, demand is rapidly growing for talent across: Computational Biology Bioinformatics AI/ML Medicinal Chemistry Translational Research Data Science Do you think AI-driven drug discovery will significantly reduce development timelines and improve clinical success rates over the next decade? Or do you think the industry is still too early for the technology to fully deliver on the hype? Read the Full Article Here: https://loom.ly/lsMjh2A #Biotech #Biopharma #DrugDiscovery #AI #Bioinformatics #BiotechNews #BiotechIndustry

What stands out most in client feedback isn’t just outcomes, it’s the experience of working together. Consistent themes we hear: a true sense of partnership, quick and clear communication, a professional approach, and the ability to move efficiently without sacrificing quality. That’s the standard we aim to deliver on every search. If you’re looking for a recruiting partner who operates as an extension of your team, let’s connect: info@sci.bio #ClientFeedback #LifeSciences #Biotech #Recruiting #Partnership

The life sciences hiring landscape heading into 2026 is evolving, but not in a straight line. We’re seeing a market shaped by more selective hiring, longer evaluation cycles, increased use of contract roles, and a sharper focus on specialized skill sets across biotech and pharma. This carousel highlights 7 key insights from BioSpace that help employers and candidates better understand where the market is headed, and how to adapt accordingly. At Sci.bio Recruiting, we’re working directly in these shifts every day, helping teams stay competitive and candidates position themselves effectively in a more nuanced hiring environment. Our own Eric Celidonio was also featured in this article, sharing a perspective on the evolving hiring landscape. If you’re navigating biotech hiring in 2026, Sci.bio Recruiting is here to make the process stress-free. Connect with us today → info@sci.bio Read more: https://lnkd.in/e2JJm9G3 #LifeSciences #BiotechHiring #2026JobMarket #TalentAcquisition #BiotechRecruiting

Another week in biotech and biopharma, and the industry continues to move at full speed. Over the last several days alone, we’ve seen workforce restructuring, major acquisitions, and continued shifts in strategy across the sector. This week, Gilead made headlines after announcing another round of layoffs tied to its recent Arcellx acquisition. The cuts impacted employees across California and Maryland as the company continues integrating operations following the $7.8B deal. It’s another example of how consolidation remains a major theme throughout biotech in 2026. https://loom.ly/BJ2xpoU On the smaller biotech side, Passage Bio announced plans to reduce its workforce by 75% after the FDA pushed back on the company’s proposed development path for its lead gene therapy candidate. Regulatory uncertainty continues to create major ripple effects for emerging biotech companies trying to balance innovation with increasingly difficult funding environments. https://loom.ly/sUBoDvI M&A activity also remained strong this week. Angelini Pharma announced a $4.1B agreement to acquire Catalyst Pharmaceuticals, strengthening its position in rare neurological diseases and expanding its footprint in the U.S. market. Even with broader market volatility, companies continue looking externally for pipeline growth opportunities. https://loom.ly/qyGnLgY Between restructuring efforts, regulatory hurdles, and continued acquisition activity, one thing remains clear: the biotech and biopharma industry isn’t slowing down anytime soon. It will be interesting to see what the rest of Q2 brings. #Biotech #Biopharma #LifeSciences #Pharma #DrugDevelopment #Biotechnology #FDA #BiotechNews #PharmaIndustry